Teemu Junttila PhD

Teemu Junttila was joined Genentech in 2006, initially as a postdoctoral fellow. He transitioned to leading a research team in 2010. His research can be rapidly guided by clinical signals without delay, which Ihefind extremely motivating and rewarding. His role is to lead large molecule biology research that translates new antibody engineering technologies into oncology therapeutics. Currently, focusing on bispecific antibodies that can be used to redirect T cells to attack tumors.